13.57
price down icon6.93%   -1.01
after-market After Hours: 13.59 0.02 +0.15%
loading
Kalvista Pharmaceuticals Inc stock is traded at $13.57, with a volume of 1.89M. It is down -6.93% in the last 24 hours and up +18.93% over the past month. KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
See More
Previous Close:
$14.58
Open:
$14.6
24h Volume:
1.89M
Relative Volume:
1.72
Market Cap:
$677.87M
Revenue:
-
Net Income/Loss:
$-156.39M
P/E Ratio:
-3.6775
EPS:
-3.69
Net Cash Flow:
$-123.06M
1W Performance:
-12.79%
1M Performance:
+18.93%
6M Performance:
+52.99%
1Y Performance:
-8.25%
1-Day Range:
Value
$13.55
$14.78
1-Week Range:
Value
$13.55
$15.97
52-Week Range:
Value
$7.30
$16.32

Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile

Name
Name
Kalvista Pharmaceuticals Inc
Name
Phone
(857) 999-0075
Name
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Name
Employee
270
Name
Twitter
@kalvista
Name
Next Earnings Date
2025-03-12
Name
Latest SEC Filings
Name
KALV's Discussions on Twitter

Compare KALV with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
KALV
Kalvista Pharmaceuticals Inc
13.57 728.33M 0 -156.39M -123.06M -3.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
460.83 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.63 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.79 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
595.19 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.51 31.54B 3.81B -644.79M -669.77M -6.24

Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-31-25 Initiated JMP Securities Mkt Outperform
Jan-07-25 Initiated TD Cowen Buy
Dec-18-24 Initiated BofA Securities Buy
Jun-15-20 Initiated H.C. Wainwright Buy
Jul-29-19 Initiated SVB Leerink Outperform
Mar-20-19 Initiated Needham Buy
Oct-30-18 Initiated Jefferies Buy
Sep-21-18 Initiated Cantor Fitzgerald Overweight
Aug-31-17 Initiated BTIG Research Buy
View All

Kalvista Pharmaceuticals Inc Stock (KALV) Latest News

pulisher
01:42 AM

KalVista Pharmaceuticals (KALV) Received Positive Opinion From the European Medicines Agency - Insider Monkey

01:42 AM
pulisher
Jul 28, 2025

What institutional investors are buying KalVista Pharmaceuticals Inc. stockUnlock daily market insights for better trades - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

What is the dividend policy of KalVista Pharmaceuticals Inc. stockBreakthrough investment results - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are analysts’ price targets for KalVista Pharmaceuticals Inc. in the next 12 monthsUnlock high-yield investment opportunities - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

KalVista Pharmaceuticals Faces Downgrade Due to Shrinking Market and Oral Competitor Threat - AInvest

Jul 27, 2025
pulisher
Jul 27, 2025

KalVista Pharmaceuticals Ekterly Faces A Shrinking Market And Oral Competitor Threat (Downgrade) - Seeking Alpha

Jul 27, 2025
pulisher
Jul 25, 2025

Kalvista Pharmaceuticals shares rise 1.17% after-hours following positive CHMP opinion for sebetralstat. - AInvest

Jul 25, 2025
pulisher
Jul 25, 2025

EMA’s CHMP adopts five orphans - BioCentury

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about KalVista Pharmaceuticals Inc. stock outlookPhenomenal capital gains - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

New medicines recommended for approval by EMA’s CHMP - The Pharma Letter

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about KalVista Pharmaceuticals Inc. stockFree Daily Trading Room Entry - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

KalVista receives CHMP opinion recommending sebetralstat marketing authorization - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

KalVista, Biogen, Ionis get EU positive opinions for key drugs (KALV:NASDAQ) - Seeking Alpha

Jul 25, 2025
pulisher
Jul 25, 2025

European regulator recommends approval of first oral HAE treatment - Investing.com India

Jul 25, 2025
pulisher
Jul 25, 2025

KalVista Pharma Announces Positive CHMP Opinion For Sebetralstat - Nasdaq

Jul 25, 2025
pulisher
Jul 25, 2025

KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks - Business Wire

Jul 25, 2025
pulisher
Jul 25, 2025

What drives KalVista Pharmaceuticals Inc. stock priceFree Daily Trading Room Entry - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

US FDA Cancer Reviewers Heading For The Exits, Potentially Impacting Review Timelines - insights.citeline.com

Jul 24, 2025
pulisher
Jul 23, 2025

KalVista Pharmaceuticals Inc. Stock Analysis and ForecastRobust investment performance - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Is KalVista Pharmaceuticals Inc. a good long term investmentRapid return acceleration - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com

Jul 21, 2025
pulisher
Jul 17, 2025

Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP - Investing.com India

Jul 17, 2025
pulisher
Jul 16, 2025

(KALV) Proactive Strategies - news.stocktradersdaily.com

Jul 16, 2025
pulisher
Jul 16, 2025

JMP reiterates Market Outperform rating on Kalvista stock after UK approval By Investing.com - Investing.com South Africa

Jul 16, 2025
pulisher
Jul 16, 2025

JMP reiterates Market Outperform rating on Kalvista stock after UK approval - Investing.com Nigeria

Jul 16, 2025
pulisher
Jul 16, 2025

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - BioSpace

Jul 16, 2025
pulisher
Jul 15, 2025

KalVista Pharmaceuticals Gets UK Approval for Hereditary Angioedema Treatment - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

KalVista Pharmaceuticals announces UK MHRA approval of Ekterly (sebetralstat) - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

KalVista gets UK nod for Ekterly (KALV:NASDAQ) - Seeking Alpha

Jul 15, 2025
pulisher
Jul 15, 2025

UK approves first oral treatment for hereditary angioedema attacks By Investing.com - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

(sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire

Jul 15, 2025
pulisher
Jul 15, 2025

MHRA approves Ekterly to treat HAE - The Pharma Letter

Jul 15, 2025
pulisher
Jul 15, 2025

KalVista Pharmaceuticals Wins UK Approval for Hereditary Angioedema Treatment - MarketScreener

Jul 15, 2025

Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.09
price down icon 1.32%
$37.06
price up icon 1.06%
$101.75
price down icon 2.12%
$27.45
price down icon 4.26%
$112.79
price down icon 2.19%
biotechnology ONC
$294.51
price up icon 1.04%
Cap:     |  Volume (24h):